Benefits of Subcutaneous Self-Injection of FSH and HCG in a Male with Hypogonadotropic Hypogonadism

 

Patient selection: male with hypogonadotropic hypogonadism with azoospermia or aspermia from 18 to 45 years of age

 

Problems with therapy of hypogonadotropic hypogonadism:

(1) requires frequent injections

(2) response to therapy may take weeks or months

 

Benefits of subcutaneous injections:

(1) less pain

(2) greater convenience (no need to travel to a clinic 3 times a week)

(3) less time involved

(4) cheaper administration costs (purified drug might be more expensive)

(5) better compliance

(6) less erratic serum levels

 

All of these features result in better therapeutic outcomes.